ARTICLE SUMMARY:
Koelis' Trinity system integrates advanced image-guidance technologies for prostate biopsy and focal treatment to track the movement of the prostate itself, unlike other solutions that track only the ultrasound probe.
Founded in 2006, Koelis is headquartered in Grenoble, France, with US offices in Princeton, NJ. The company is funded in part by private equity firm InnovaHealth Partners, which acquired a majority interest in Koelis in 2019 and led a€10 million follow-on growth equity financing that closed in April 2022.
Koelis is focused on advanced image-guidance technologies for prostate biopsy and focal treatment, and thus is taking an adjunctive role as an “enabling technology” to targeted prostate interventions. Koelis began by applying image fusion guidance (fusing MRI and ultrasound images) to prostate biopsy procedures. According to co-founder and CEO Antoine Leroy, the company now sells its Trinity 3D MRI-US fusion image guidance system in nearly 50 countries worldwide, including the US, where it is 510(k) cleared for mapping and guidance and has been in use for more than 10 years.
